North American prazosin market is estimated to decline at a CAGR of around -1.9% during the forecast period. Moreover, the discontinuation of prazosin drug manufacturing by various companies also showcases the low opportunity in the market. In the US, Pfizer has discontinued Minipress XL, Minizide, and only marketing Minipress. Other companies including Watson Labs, Ani Pharms Inc., Dava Pharms Inc., Purepac Pharm has already discontinued the manufacturing of prazosin hydrochloride in the US market. Lower sales of the branded drug are also restraining the growth of the market. As per ClinCalc LLC (an online medical resource tool website), the prescription of prazosin in the US was increased to 2.4 million in 2016 from around 1.0 million in 2014. After 2016, the number of prescriptions of prazosin is expected to decrease continuously in the near future.
Visit for Global Prazosin Market Report at: https://www.omrglobal.com/industry-reports/prazosin-market
The North American prazosin market is segmented on the basis of application. Based on the application, the market is segmented into cardiovascular disease, neurological syndromes, prostate disorders, and kidney disorders. The CVD segment accounted for the significant share in the North American prazosin market. CVDs claim to take more lives each year than all forms of cancer and chronic lower respiratory diseases altogether. Thus, Prazosin is one of the treatments used for CVD mainly high BP and strokes. For instance, Minipress is specified for the treatment of hypertension, to control BP. Lowering blood pressure decreases the risk of fatal and nonfatal cardiovascular events, mainly strokes and myocardial infarction.
The companies which are contributing to the growth of the North American prazosin market include Apotex Inc., Teva Pharmaceuticals Industries Ltd., Cayman Chemical Co., Pfizer Inc., R&D Systems Inc., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.
Research Methodology
The market study of the North American prazosin market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for prazosin market players, potential entrants, and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, products offered by the market players, and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints/Challenges
4.3. Opportunities
5. Market Segmentation
5.1. North American Prazosin Market by Application
5.1.1. Cardiovascular Disease(CVD)
5.1.2. Neurological Syndromes
5.1.3. Prostate Disorders
5.1.4. Kidney Disorders
6. Regional Analysis
6.1. US
6.2. Canada
7. Company Profiles
7.1. Apotex Inc.
7.2. Axon Medchem LLC
7.3. Cayman Chemical Co.
7.4. Merck KGaA
7.5. NovitiumPharma
7.6. Pfizer Inc.
7.7. R&D Systems Inc.
7.8. Mylan N.V.
7.9. Teva Pharmaceuticals Industries Ltd.
7.10. TRC Inc.
1. NORTH AMERICAN PRAZOSIN MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
2. NORTH AMERICAN PRAZOSIN FOR CVD MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
3. NORTH AMERICAN PRAZOSIN FOR NEUROLOGICAL SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
4. NORTH AMERICAN PRAZOSIN FOR PROSTATE DISORDERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
5. NORTH AMERICAN PRAZOSIN FOR KIDNEY DISORDERS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
6. NORTH AMERICAN PRAZOSIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
1. NORTH AMERICAN PRAZOSIN MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)
2. NORTH AMERICAN PRAZOSIN MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
3. US PRAZOSIN MARKET SIZE, 2019-2026 ($ MILLION)
4. CANADA PRAZOSIN MARKET SIZE, 2019-2026 ($ MILLION)